News
QNTM
3.800
+17.65%
0.570
Quantum BioPharma GAAP EPS of -$0.47
Seeking Alpha · 1d ago
Quantum BioPharma Boosts Liquidity as FDA Clears Pivotal Lucid-MS Phase 2 Trial
TipRanks · 1d ago
*Quantum BioPharma: Runway to at Least October 2027 at Current Budgeted Spend >QNTM
Dow Jones · 1d ago
Press Release: Quantum BioPharma Strengthens -2-
Dow Jones · 1d ago
Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
Dow Jones · 1d ago
Quantum Biopharma Posts Higher Assets and Losses in Q2 2026 Filing
TipRanks · 2d ago
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
TipRanks · 2d ago
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial
TipRanks · 5d ago
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2
TipRanks · 5d ago
Quantum Group receives FDA clearance to proceed with Lucid-MS trial
TipRanks · 5d ago
Quantum BioPharma Wins FDA Green Light for Phase 2 Lucid-MS Trial in Progressive Multiple Sclerosis
TipRanks · 5d ago
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial
Benzinga · 5d ago
Weekly Report: what happened at QNTM last week (0803-0807)?
Weekly Report · 5d ago
3 Quantum Computing ETFs with Over 23% Upside Potential, According to Analysts
TipRanks · 08/05 16:04
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results
TipRanks · 08/03 17:30
Weekly Report: what happened at QNTM last week (0727-0731)?
Weekly Report · 08/03 10:13
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans
TipRanks · 07/28 17:00
2 Quantum Computing ETFs with Over 50% Upside Potential, According to Analysts
TipRanks · 07/27 15:38
Weekly Report: what happened at QNTM last week (0720-0724)?
Weekly Report · 07/27 10:17
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions
TipRanks · 07/22 16:30
More
Webull provides a variety of real-time QNTM stock news. You can receive the latest news about Quantum BioPharma Ltd through multiple platforms. This information may help you make smarter investment decisions.
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.